Once-daily boosted darunavir as a new therapeutic option for treatment-experienced HIV-infected patients
HIV & AIDS Review · 2011
DOI: 10.1016/j.hivar.2011.07.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV & AIDS Review, 2011. Verfasst von Magdalena M. Dabrowska und 1 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Darunavir (DRV) is a new, second-generation PI approved by FDA (Food and Drug Administration) and EMEA (European Medicines Agency) as a therapeutic option for treatment-experienced HIV-infected patients with resistance to other available PIs in twice-daily 600/100 mg dose or for treatment-naïve HIV-infected patients in once-daily 800/100 mg dose. In December 2010 the FDA revised its approval of DRV/r, recommending 800/100 mg once-daily dose for HIV-infected treatment-experienced patients with no baseline resistance-associated mutations to DRV. This paper is a small review of all studies concerning DRV/r therapy in treatment-experienced HIV-infected patients.
Zitieren
APA
Dabrowska, M. M., & Kozlowska, J. (2011). Once-daily boosted darunavir as a new therapeutic option for treatment-experienced HIV-infected patients. HIV & AIDS Review. https://doi.org/10.1016/j.hivar.2011.07.002
Vancouver
Dabrowska MM, Kozlowska J. Once-daily boosted darunavir as a new therapeutic option for treatment-experienced HIV-infected patients. HIV & AIDS Review. 2011. doi:10.1016/j.hivar.2011.07.002
BibTeX
@article{Dabrowska2011,
author = {Dabrowska, Magdalena M. and Kozlowska, Joanna},
title = {Once-daily boosted darunavir as a new therapeutic option for treatment-experienced HIV-infected patients},
journal = {HIV & AIDS Review},
year = {2011},
doi = {10.1016/j.hivar.2011.07.002}
}
EUVIMED